Teva Pharmaceutical Industries ADR TEVA

$41.47 +1.50 (3.75%)

Valuation

Market cap
45,423,240,000
Revenue TTM
$17,258,000,000
Net income TTM
$1,411,000,000
PE ratio
17.98
Forward PE
19.74
Profit margin
8.18%
Debt to equity
2.14

Trading

Volume
5,230,100
Avg volume
5,559,212
Day's range
$40.01 – $41.67
Shares out
1,165,296,000
Stochastic %K
31%
Beta
0.87
Analysts
Strong Sell
Price target
$46.62

Price

Company profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cyto...

Show more

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
972 3 914 8213
Website
https://www.tevapharm.com
Address
124 Dvora HaNevi’a St., Tel Aviv-Yafo, Israel

Latest news

Stocktwits

Orbit100 Oct 29, 5:33 PM
$TEVA My Amgen stock hit another 52 week high. See Teva to $45. TEVA is a strong valued stock that continues making its great mark for its product lines and business.
0 replies
thatsolardude365 Oct 29, 3:35 PM
$TEVA: the fee math in QVAR. Counsel reportedly sought up to $11.5M from the $35M Teva antitrust fund, leaving about $23.5M before admin costs for pro rata claims. Claims closed July 31. Open Class Actions.
0 replies
GDS_investing Oct 29, 3:23 PM
$TEVA $BHC yes !
0 replies
GDS_investing Oct 28, 8:07 PM
$TEVA went from 7 to 42. Now it’s $BHC turn. long
0 replies
Menashes Oct 28, 1:39 PM
$TEVA now liquidity was properly generated and big guys can load hard at this level.
0 replies
Menashes Oct 28, 1:25 PM
$TEVA pre market bad because of the worries about TASE. Then the TASE is doing great. Just bullish.
0 replies
thatsolardude365 Oct 28, 8:26 AM
$TEVA: who counted in QVAR? Buyers in 41 states plus DC who paid for the asthma inhaler from Jan. 2015 to July 2025. The $35M antitrust deal pays pro rata, claims closed July 31. Open Class Actions.
0 replies
TradeThePool Oct 27, 9:04 PM
Is Google quietly becoming Big Pharma’s new king? $GOOGL Alphabet reports Q3 tomorrow. Analysts will watch cloud and the ~$200B capex budget. The bigger story sits inside DeepMind and Isomorphic Labs. Google does not need factories. It owns the models that design the molecules. AlphaFold mapped 200M+ proteins. AlphaGenome Atlas covers ~9B DNA variants. Isomorphic already has deals with $LLY and Novartis worth up to $3B. A manufacturing partner like $TEVA would complete the chain. Not priced yet. First clinical trials are the catalyst. #GOOGL #AI #Pharma #Biotech
0 replies